Built by Someone Who's Been in the Room

The Observation

I spent over two decades watching clients pay $300K for 90-page strategy documents that were outdated by the time they were delivered. The consultants were brilliant people. But the model — fixed-fee projects, analyst hour billing, 6–12 week timelines — was designed for a world without AI.

What Changed

Around 2023, I started noticing something uncomfortable: the junior analysts at top consulting firms were already using AI to generate first drafts. The senior partner reviewed it, put their name on it, and charged the same rate as before. The efficiency gains were going to the firm, not the client.

The Thesis

ValOracle is built on one premise: market access intelligence should be always-on, not episodic. Instead of commissioning a new engagement every time you have a question, you should have a platform that answers it — backed by expert judgment, not just AI output.

We're not replacing the expert. We're replacing the engagement model. The expert is still in the loop — reviewing every output, adding judgment, ensuring accuracy. But they're doing it 10x faster, which means you pay 10x less.

Why OaaS

The term "Outcome as a Service" is deliberate. We don't sell software licenses or consulting hours. We sell outcomes: a formulary landscape, a pricing recommendation, a payer profile, a value dossier. You consume what you need, when you need it.

This is what market access support should have looked like for the last decade. We're just the first to build it.

Who We Serve

ValOracle is designed for mid-market biotech (50–500 employees) with 1–5 pipeline assets — companies that need enterprise-grade market access intelligence but can't justify a $2M annual consulting retainer. We also work with independent consultants who white-label our platform, and large pharma teams who want to run portfolio-scale assessments without scaling headcount.